415 related articles for article (PubMed ID: 25381970)
1. Clinical markers predictive of primary inefficacy: a "real life" retrospective study in psoriatic patients treated with etanercept.
Giunta A; Babino G; Manetta S; Mazzotta A; Chimenti S; Esposito M
Drug Dev Res; 2014 Nov; 75 Suppl 1():S27-30. PubMed ID: 25381970
[TBL] [Abstract][Full Text] [Related]
2. Etanercept for psoriasis: two case reports.
Fidalgo A; Baptista J; Rocha Páris F; Caldas Lopes L; Ferreira A
Int J Clin Pharmacol Res; 2005; 25(4):159-63. PubMed ID: 16402631
[TBL] [Abstract][Full Text] [Related]
3. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
[TBL] [Abstract][Full Text] [Related]
4. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
7. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
Mease PJ
Skin Therapy Lett; 2003 Jan; 8(1):1-4. PubMed ID: 12728284
[TBL] [Abstract][Full Text] [Related]
8. [Clinical experience with etanercept in the treatment of psoriasis].
Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
[TBL] [Abstract][Full Text] [Related]
9. Two years of experience with etanercept in recalcitrant psoriasis.
Ahmad K; Rogers S
Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
[TBL] [Abstract][Full Text] [Related]
10. Baseline anti-dsDNA concentrations and previous treatments predict response to Adalimumab and Etanercept: a retrospective investigation of 146 psoriasis patients.
Hoffmann JH; Knoop C; Enk AH; Hadaschik EN
J Dermatol Sci; 2014 Dec; 76(3):180-5. PubMed ID: 25306295
[TBL] [Abstract][Full Text] [Related]
11. Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study.
Lestre S; Diamantino F; Veloso L; Fidalgo A; Ferreira A
Eur J Dermatol; 2011; 21(6):916-20. PubMed ID: 21983007
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy study on etanercept in patients with plaque psoriasis.
Costanzo A; Mazzotta A; Papoutsaki M; Nisticò S; Chimenti S
Br J Dermatol; 2005 Jan; 152(1):187-9. PubMed ID: 15656833
[No Abstract] [Full Text] [Related]
13. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions].
Paul C; Solignac M
Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):13-5. PubMed ID: 20510165
[No Abstract] [Full Text] [Related]
14. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept.
Kanelleas A; Liapi C; Katoulis A; Stavropoulos P; Avgerinou G; Georgala S; Economopoulos T; Stavrianeas NG; Katsambas A
Clin Exp Dermatol; 2011 Dec; 36(8):845-50. PubMed ID: 21790728
[TBL] [Abstract][Full Text] [Related]
15. TNFalpha and its receptors in psoriatic skin, before and after treatment with etanercept.
Caldarola G; De Simone C; Carbone A; Tulli A; Amerio P; Feliciani C
Int J Immunopathol Pharmacol; 2009; 22(4):961-6. PubMed ID: 20074459
[TBL] [Abstract][Full Text] [Related]
16. Etanercept for the treatment of psoriasis: combination therapy with other modalities.
Strober BE; Clarke S
J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161
[TBL] [Abstract][Full Text] [Related]
17. Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24.
Wang F; Smith N; Maier L; Xia W; Hammerberg C; Chubb H; Chen C; Riblett M; Johnston A; Gudjonsson JE; Helfrich Y; Kang S; Fisher GJ; Voorhees JJ
Br J Dermatol; 2012 Jul; 167(1):92-102. PubMed ID: 22458549
[TBL] [Abstract][Full Text] [Related]
18. Etanercept in psoriasis.
Papp KA
Expert Opin Pharmacother; 2004 Oct; 5(10):2139-46. PubMed ID: 15461549
[TBL] [Abstract][Full Text] [Related]
19. Clinical and economic impact of etanercept in real-life: a prospective, non-interventional study of etanercept in the treatment of patients with moderate to severe plaque psoriasis in private dermatologist settings (ESTHER).
Larsen CG; Andersen PH; Lorentzen H; Zachariae C; Huldt-Nystrøm T; Dotterud LK; Lindkvist RM; Qvitzau S
Eur J Dermatol; 2013; 23(6):774-81. PubMed ID: 24334009
[TBL] [Abstract][Full Text] [Related]
20. Psoriasis and hepatitis C treated with anti-TNF alpha therapy (etanercept).
Cecchi R; Bartoli L
Dermatol Online J; 2006 Dec; 12(7):4. PubMed ID: 17459290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
